Tina Vilsbøll Selected Research

Incretins

12/2020	No detectable effect of a type 2 diabetes-associated TCF7L2 genotype on the incretin effect.
11/2020	Normal insulin sensitivity, glucose tolerance, gut incretin and pancreatic hormone responses in adults with atopic dermatitis.
9/2020	Circulating Levels of the Soluble Receptor for AGE (sRAGE) during Escalating Oral Glucose Dosages and Corresponding Isoglycaemic i.v. Glucose Infusions in Individuals with and without Type 2 Diabetes.
1/2020	GIP's effect on bone metabolism is reduced by the selective GIP receptor antagonist GIP(3-30)NH2.
1/2020	Effects of Gender-Affirming Hormone Therapy on Insulin Sensitivity and Incretin Responses in Transgender People.
1/2020	No Acute Effects of Exogenous Glucose-Dependent Insulinotropic Polypeptide on Energy Intake, Appetite, or Energy Expenditure When Added to Treatment With a Long-Acting Glucagon-Like Peptide 1 Receptor Agonist in Men With Type 2 Diabetes.
1/2020	GIP and GLP-1 Potentiate Sulfonylurea-Induced Insulin Secretion in Hepatocyte Nuclear Factor 1α Mutation Carriers.
8/2019	The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion-A Review.
3/2019	[Glucagon-like peptide 1 receptor agonists for the treatment of Type 2 diabetes].
1/2019	Separate and Combined Effects of GIP and GLP-1 Infusions on Bone Metabolism in Overweight Men Without Diabetes.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Tina Vilsbøll Research Topics

Disease

159	Type 2 Diabetes Mellitus (MODY) 10/2022 - 09/2003
44	Body Weight (Weight, Body) 01/2022 - 06/2007
29	Hypoglycemia (Reactive Hypoglycemia) 01/2022 - 09/2003
24	Insulin Resistance 05/2021 - 09/2003
22	Obesity 11/2022 - 01/2011
18	Weight Loss (Weight Reduction) 01/2021 - 02/2007
16	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 10/2022 - 04/2010
16	Hyperglycemia 01/2022 - 01/2008
15	Overweight 01/2022 - 01/2011
12	Weight Gain 02/2020 - 07/2008
9	Bone Resorption 01/2022 - 12/2003
9	Cardiovascular Diseases (Cardiovascular Disease) 12/2021 - 01/2012
9	Non-alcoholic Fatty Liver Disease 08/2021 - 04/2016
7	Schizophrenia (Dementia Praecox) 01/2022 - 06/2013
7	Glucose Intolerance 01/2021 - 04/2012
7	Chronic Pancreatitis 11/2012 - 09/2003
6	Inflammation (Inflammations) 11/2022 - 11/2015
5	Heart Failure 01/2022 - 01/2019
5	Prediabetic State (Prediabetes) 01/2022 - 01/2017
5	Myocardial Infarction 01/2021 - 07/2016
5	Stroke (Strokes) 01/2020 - 07/2016
5	Diabetes Mellitus 10/2018 - 09/2006
4	Gestational Diabetes (Gestational Diabetes Mellitus) 10/2020 - 01/2007
4	Nausea 01/2020 - 02/2007
4	Type 3 Maturity-Onset Diabetes of the Young 01/2018 - 07/2014
3	Albuminuria 09/2021 - 01/2016
3	Chronic Renal Insufficiency 01/2021 - 01/2019
3	Diabetes Complications 09/2020 - 02/2009
3	Fibrosis (Cirrhosis) 01/2019 - 10/2015
3	Liver Diseases (Liver Disease) 01/2019 - 01/2018
3	Psoriasis (Pustulosis Palmaris et Plantaris) 04/2015 - 12/2011
2	Cardiac Arrhythmias (Arrythmia) 12/2021 - 07/2021
2	Metabolic Diseases (Metabolic Disease) 04/2021 - 01/2020

Drug/Important Bio-Agent (IBA)

105	Glucose (Dextrose)FDA LinkGeneric 10/2022 - 09/2003
67	Glucagon-Like Peptide 1 (GLP 1)IBA 10/2021 - 09/2003
52	Insulin (Novolin)FDA Link 01/2022 - 09/2003
45	Glucagon (Glukagon)FDA Link 01/2022 - 01/2008
41	Hormones (Hormone)IBA 11/2021 - 12/2003
37	IncretinsIBA 12/2020 - 11/2004
30	Peptides (Polypeptides)IBA 10/2022 - 08/2005
28	Liraglutide FDA Link 01/2022 - 02/2007
25	Glucagon-Like Peptide-1 ReceptorIBA 01/2022 - 05/2010
17	Glucagon-Like Peptide-1 Receptor AgonistsIBA 01/2022 - 01/2008
17	Metformin (Glucophage)FDA LinkGeneric 06/2021 - 01/2008
12	semaglutideIBA 10/2021 - 11/2016
11	Biomarkers (Surrogate Marker)IBA 11/2022 - 01/2018
10	Exenatide (Byetta)FDA Link 01/2022 - 05/2010
10	LipidsIBA 01/2021 - 05/2010
9	C-PeptideIBA 01/2022 - 08/2005
8	Hypoglycemic Agents (Hypoglycemics)IBA 10/2021 - 07/2008
8	IDegLiraIBA 02/2020 - 11/2014
8	Bile Acids and Salts (Bile Acids)IBA 01/2020 - 01/2012
7	Antipsychotic Agents (Antipsychotics)IBA 01/2022 - 03/2014
7	insulin degludecIBA 02/2020 - 05/2015
6	Dipeptidyl-Peptidase IV InhibitorsIBA 10/2022 - 01/2011
6	Glucagon Receptors (Glucagon Receptor)IBA 01/2022 - 01/2011
6	Collagen Type I (Type I Collagen)IBA 01/2022 - 12/2003
6	Olanzapine (Zyprexa)FDA Link 01/2022 - 03/2014
6	Clozapine (Clozaril)FDA LinkGeneric 01/2022 - 03/2014
6	Hemoglobins (Hemoglobin)IBA 01/2021 - 03/2015
6	Blood Glucose (Blood Sugar)IBA 01/2018 - 11/2011
5	CreatinineIBA 01/2021 - 12/2003
5	Sodium-Glucose Transport ProteinsIBA 12/2020 - 02/2016
5	EnzymesIBA 09/2020 - 01/2007
5	Pharmaceutical PreparationsIBA 01/2019 - 01/2015
5	CholesterolIBA 01/2018 - 01/2012
4	gastric inhibitory polypeptide receptorIBA 01/2022 - 01/2019
4	Insulin Glargine (Lantus)FDA Link 01/2020 - 12/2015
4	Triglycerides (Triacylglycerol)IBA 01/2020 - 01/2012
4	Hepatocyte Nuclear FactorsIBA 01/2020 - 07/2014
4	Dipeptidyl Peptidase 4 (Dipeptidyl Peptidase IV)IBA 08/2015 - 09/2006
4	Gastrointestinal Hormones (Hormones, Gastrointestinal)IBA 06/2014 - 12/2003
3	Sitagliptin Phosphate (Januvia)FDA Link 10/2022 - 01/2008
3	Brain Natriuretic Peptide (Natrecor)FDA Link 09/2021 - 02/2019
3	CollagenIBA 05/2021 - 01/2018
3	fibroblast growth factor 21IBA 05/2021 - 01/2018
3	Messenger RNA (mRNA)IBA 01/2021 - 01/2018
3	Cholecystokinin (Pancreozymin)IBA 01/2021 - 11/2017
3	empagliflozinIBA 12/2020 - 09/2016
3	ProcollagenIBA 11/2020 - 01/2019
3	8-Hydroxy-2'-DeoxyguanosineIBA 09/2020 - 01/2020
3	Nucleic AcidsIBA 09/2020 - 01/2017
3	Gastric Inhibitory Polypeptide (Glucose Dependent Insulinotropic Peptide)IBA 01/2020 - 12/2006
3	RNA (Ribonucleic Acid)IBA 01/2020 - 01/2019
3	dapagliflozinIBA 01/2020 - 02/2016
3	Sevelamer (RenaGel)FDA Link 01/2020 - 01/2018
3	HDL CholesterolIBA 01/2019 - 01/2012
3	lixisenatideIBA 03/2017 - 04/2011
2	adomeglivantIBA 01/2022 - 12/2020
2	InterleukinsIBA 01/2022 - 09/2020
2	CytokinesIBA 01/2022 - 09/2020
2	gastric inhibitory polypeptide (3-30)-amideIBA 05/2021 - 01/2020
2	omega-Chloroacetophenone (Mace)IBA 01/2021 - 01/2020

Therapy/Procedure

36	Therapeutics 01/2022 - 09/2003
17	Glycemic Control 10/2022 - 06/2007
8	Gastric Bypass (Roux-en-Y Gastric Bypass) 01/2022 - 12/2011
5	Subcutaneous Injections 01/2022 - 09/2003
5	Intravenous Infusions 01/2022 - 04/2016
3	Bariatric Surgery 08/2017 - 12/2011
2	Aftercare (After-Treatment) 01/2021 - 06/2013